Dual peptide-mediated targeted delivery of bioactive siRNAs to oral cancer cells in vivo

Oral and pharyngeal cancer is the ninth most common cancer worldwide [1], and in the U.S.A. it is estimated that about 50,000 new cases and approximately 10,000 deaths occur annually due to cancer of the oral cavity and pharynx [2]. Although significant advances have been made in cancer treatment, the prognosis for oral cancer remains poor in comparison to other cancer types, including breast, skin, and prostate [2]. Moreover, the five-year survival rate for all stages of oral cancer is 64% and has only modestly improved over the past few decades [2,3].

http://ift.tt/2wCDB0r